Company profile
DENTSPLY SIRONA Inc.
NASDAQ:XRAYMedical/Dental Instruments
Drug pipeline (9)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Epinephrine | approved | — | 1 | approved |
| Epinephrine bitartrate | approved | — | 0 | — |
| ETIDOCAINE HYDROCHLORIDE | approved | — | 0 | — |
| LEVONORDEFRIN | approved | — | 0 | — |
| Lidocaine | approved | — | 1 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01591616 | phase4 | completed | 2010-04-01 | 2012-04-01 | Dentsply International | Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel |
FDA applications (8)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 088653 | ANDA | DENTSPLY PHARMACEUTICAL | ||||
Loading… | ||||||
| ANDA 089517 | ANDA | DENTSPLY PHARMACEUTICAL | ||||
Loading… | ||||||
| NDA 021380 | NDA | DENTSPLY PHARMACEUTICAL INC | ||||
Loading… | ||||||
| NDA 021381 | NDA | DENTSPLY PHARMACEUTICAL INC | ||||
Loading… | ||||||
| NDA 021382 | NDA | DENTSPLY PHARMACEUTICAL INC | ||||
Loading… | ||||||